This approach is of particular relevance given that TLR7 antibody drug conjugates (TLR7-ADCs) targeting human epidermal growth factor receptor 2 have shown promising antitumor inflammatory responses in mouse models and early clinical trials (62, 63); however, the benefits of tumor antigen targeting and Fcγ receptor–mediated phagocytosis come with significant issues such as highly limited drug loading, antidrug antibodies and other immunotoxicities that were associated with decreases in drug exposure in clinical studies (64). Here, TLR7 is linked to neoplasm.